Severity
Moderate
FDA Drug recall · Reported January 29, 2014
Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) may have potentially been mislabeled as the following drug:, LUBIPROSTONE, Capsule, 24 mcg, NDC 6476402406…
Aidapak Services, LLC recalled CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg), Rx only, Distributed by: AidaPak Service… - a moderate-severity action.
CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg), Rx only, Distributed by: AidaPak Service… was recalled by Aidapak Services, LLC in January 29, 2014. Reason: Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) may have potentially been mislabeled a…. Check the official notice for the remedy. Verify recall #D-864-2014 with the FDA Drug before acting.
The recall
Aidapak Services, LLC issued this moderate-severity FDA Drug recall-Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) may have potentially been mislabeled a….
Sourced from official FDA Drug enforcement records. Verify recall #D-864-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-864-2014) was formally reported on January 29, 2014, with the manufacturer initiating the action on July 2, 2013. It is classified under Moderate severity (Class II), with a current status of Terminated. Aidapak Services, LLC is listed as the recalling firm, operating out of Vancouver, WA. Federal records list the affected scope as 200 Tablets.
The documented reason for this recall is: Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) may have potentially been mislabeled as the following drug:, LUBIPROSTONE, Capsule, 24 mcg, NDC 64764024060, Pedigree: AD46312_1, EXP: 5/16/2014. Distribution data in the federal record shows the product reached: Repacked drugs were distributed in Arizona, California, Oregon, and Washington.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
200 Tablets
Related Recalls
6
5 from same agency
CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00143117101.
Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) may have potentially been mislabeled as the following drug:, LUBIPROSTONE, Capsule, 24 mcg, NDC 64764024060, Pedigree: AD46312_1, EXP: 5/16/2014.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-864-2014 |
| Date reported | January 29, 2014 |
| Date initiated | July 2, 2013 |
| Recalling firm | Aidapak Services, LLC |
| Firm location | Vancouver, WA |
| Affected scope | 200 Tablets |
| Distribution | Repacked drugs were distributed in Arizona, California, Oregon, and Washington. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 29, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.